Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
OTC Drugs

Aleve’s “Rated #1” Claims Unsupported By Survey Design – NAD

This article was originally published in The Tan Sheet

  • News

Executive Summary

Bayer Consumer Healthcare should modify product claims that imply Aleve is the number one pick among orthopedic surgeons for minor arthritis pain, the National Advertising Division of the Council of Better Business Bureaus recommends

You may also be interested in...



FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns

The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products

FTC Views Testimonials As Efficacy Claims, Senior Attorney Warns

The Federal Trade Commission's senior staff attorney for advertising practices recommends firms stay away from using consumer testimonials to assert the benefits of their products

GMP Compliance Means Repetition In Certifying Reference Material Accuracy

Compliance with the dietary supplements good manufacturing practices final rule will require repetition in certifying the accuracy of reference materials, an Office of Dietary Supplements senior official says
Table

View full table

Topics

Tags:
OTC Drugs
UsernamePublicRestriction

Register

PS100673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By